股票代码：002750 股票简称：龙津药业 公告编号：2023-048 昆明龙津药业股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 （1）公司购买中、低风险现金管理产品，受宏观经济环境的影响较大，不 排除该项投资受到市场波动的影响； （2）公司将根据生产经营资金冗余的变化适时适量的介入，且投资品类存 在浮动收益或损失本金的可能，因此短期投资的实际收益不能准确预估； 一、进行现金管理的审批情况 昆明龙津药业股份有限公司（以下简称"公司"）于 2022 年 12 月 5 日召开 第五届董事会第十四次会议、2022 年 12 月 21 日召开 2022 年第三次临时股东大 会，审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公司及纳 入公司合并报表范围的子公司使用余额不超过人民币三亿五仟万元（35,000 万 元）的自有闲置资金进行现金管理，投资的品种包括结构性存款、理财产品、收 益凭证、集合资管（信托）计划、货币基金、国债、国债逆回购等中低风险且流 动性好的产品，公司股东大会授权董事会及管理层负责 ...

股票代码：002750 股票简称：龙津药业 公告编号：2023-047 昆明龙津药业股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、进行现金管理的审批情况 昆明龙津药业股份有限公司（以下简称"公司"）于 2022 年 12 月 5 日召开 第五届董事会第十四次会议、2022 年 12 月 21 日召开 2022 年第三次临时股东大 会，审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公司及纳 入公司合并报表范围的子公司使用余额不超过人民币三亿五仟万元（35,000 万 元）的自有闲置资金进行现金管理，投资的品种包括结构性存款、理财产品、收 益凭证、集合资管（信托）计划、货币基金、国债、国债逆回购等中低风险且流 动性好的产品，公司股东大会授权董事会及管理层负责办理具体实施相关事宜， 授权期限为股东大会审议通过之日起至一年内。 上述决策内容详见公司 2022 年 12 月 6 日、2022 年 12 月 22 日披露于深交 所网站、巨潮资讯网及指定信息披露媒体的《关于使用闲置自有资金进行现金管 ...

股票代码：002750 股票简称：龙津药业 公告编号：2023-046 昆明龙津药业股份有限公司（以下简称"公司"）于 2022 年 12 月 5 日召开 第五届董事会第十四次会议、2022 年 12 月 21 日召开 2022 年第三次临时股东大 会，审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公司及纳 入公司合并报表范围的子公司使用余额不超过人民币三亿五仟万元（35,000 万 元）的自有闲置资金进行现金管理，投资的品种包括结构性存款、理财产品、收 益凭证、集合资管（信托）计划、货币基金、国债、国债逆回购等中低风险且流 动性好的产品，公司股东大会授权董事会及管理层负责办理具体实施相关事宜， 授权期限为股东大会审议通过之日起至一年内。 上述决策内容详见公司 2022 年 12 月 6 日、2022 年 12 月 22 日披露于深交 所网站、巨潮资讯网及指定信息披露媒体的《关于使用闲置自有资金进行现金管 理的公告》（公告编号：2022-071）、《第五届董事会第十四次会议决议公告》 （公告编号：2022-073）、《2022 年第三次临时股东大会决议公告》（公告编号： 2022-075）。 三、 ...

股票代码：002750 股票简称：龙津药业 公告编号：2023-045 昆明龙津药业股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、进行现金管理的审批情况 昆明龙津药业股份有限公司（以下简称"公司"）于 2022 年 12 月 5 日召开 第五届董事会第十四次会议、2022 年 12 月 21 日召开 2022 年第三次临时股东大 会，审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公司及纳 入公司合并报表范围的子公司使用余额不超过人民币三亿五仟万元（35,000 万 元）的自有闲置资金进行现金管理，投资的品种包括结构性存款、理财产品、收 益凭证、集合资管（信托）计划、货币基金、国债、国债逆回购等中低风险且流 动性好的产品，公司股东大会授权董事会及管理层负责办理具体实施相关事宜， 授权期限为股东大会审议通过之日起至一年内。 上述决策内容详见公司 2022 年 12 月 6 日、2022 年 12 月 22 日披露于深交 所网站、巨潮资讯网及指定信息披露媒体的《关于使用闲置自有资金进行现金管 ...

Financial Performance Decline - Revenue for the reporting period decreased by 44.14% to RMB 436.34 million compared to the same period last year[22] - Net profit attributable to shareholders of the listed company decreased by 539.60% to a loss of RMB 15.78 million[22] - Net cash flow from operating activities decreased by 127.09% to a negative RMB 41.20 million[22] - Basic earnings per share decreased by 535.48% to a loss of RMB 0.0394 per share[22] - Total assets decreased by 6.88% to RMB 695.79 million compared to the end of the previous year[22] - Equity attributable to shareholders of the listed company decreased by 2.71% to RMB 567.25 million[22] - The company's main business and financial indicators showed a significant decline compared to the same period last year[22] - Revenue for the reporting period decreased by 44.14% to 43.63 million yuan, primarily due to a 67% price reduction in the centralized procurement of the company's main product[42] - Operating cash flow decreased by 127.09% to -41.20 million yuan, mainly due to reduced revenue and increased tax payments[42] - Investment cash flow decreased by 256.10% to -51.09 million yuan, primarily due to increased financial product investments and reduced investment income[42] - Net cash flow decreased by 733.21% to -92.34 million yuan, driven by reductions in operating, investment, and financing cash flows[42] - The company's total operating income decreased by 44.14% to 43,634,125.75 yuan compared to the same period last year[46] - The pharmaceutical manufacturing sector accounted for 99.67% of total operating income, with a decrease of 38.77% to 43,491,979.70 yuan[46] - The gross profit margin for the pharmaceutical manufacturing sector decreased by 18.48% to 70.83%[47] - The company's net profit attributable to the parent company decreased by 539.60% to -15,777,734.45 yuan due to reduced operating income and government subsidies[44] - Total revenue for the first half of 2023 was RMB 43.63 million, a significant decrease from RMB 78.11 million in the same period last year[149] - Operating profit for the first half of 2023 was a loss of RMB 17.74 million, compared to a loss of RMB 2.29 million in the same period last year[150] - Net profit attributable to the parent company's shareholders was a loss of RMB 15.78 million, compared to a loss of RMB 2.47 million in the same period last year[151] - Net profit for the first half of 2023 was -42,102,361.95 yuan, compared to 1,448,993.35 yuan in the same period last year, indicating a significant decline[153] - Operating cash flow for the first half of 2023 was -41,204,847.80 yuan, compared to -18,144,628.18 yuan in the same period last year, reflecting increased cash outflow[155] - Investment cash flow for the first half of 2023 was -51,088,303.65 yuan, compared to 32,727,521.11 yuan in the same period last year, showing a shift from positive to negative cash flow[155] - Sales revenue from goods and services for the first half of 2023 was 54,462,130.32 yuan, down from 89,316,999.55 yuan in the same period last year, indicating a decline in sales[155] - Credit impairment loss for the first half of 2023 was -29,130,817.48 yuan, compared to 499,383.94 yuan in the same period last year, indicating a significant increase in losses[153] - Investment income for the first half of 2023 was 2,419,160.80 yuan, compared to 3,886,572.52 yuan in the same period last year, showing a decrease[153] - Total comprehensive income for the period decreased by RMB 42,102,361.95[167] R&D and Product Development - The company has obtained a drug registration certificate for the cardiovascular chemical generic drug Bivalirudin for Injection and completed clinical and pharmaceutical reviews for one chemical generic drug[34] - The company has introduced a new TCM MAH project (Qiwai Tangmaishu Capsules for treating type 2 diabetes) and initiated secondary development and quality standard improvement research for this product[34] - The company has increased its R&D investment, with 2 invention patents authorized and 2 invention patent applications submitted[34] - R&D investment accounts for 10% of the company's sales revenue, with R&D personnel making up over 20% of total employees[37] - R&D expenditure increased by 40.76% to 14.71 million yuan, driven by increased investment in chemical generic drug development[42] - The company has a product pipeline of approximately 60 chemical generic drugs under development[37] - The company's flagship product, Longjin® Breviscapine for Injection, has a purity exceeding 98% and has been listed as a national second-class protected traditional Chinese medicine twice[38] - The adverse reaction rate of Longjin® Breviscapine for Injection decreased from 0.143% to 0.069% since 2013[38] - The company's main product, "Longjin" brand Breviscapine for Injection, is a high-purity traditional Chinese medicine injection for cardiovascular diseases[176] Investment and Subsidiary Performance - The company has acquired a controlling stake in the parent company of the new consumer brand "Earthism" to enhance its investment in the health sector[35] - The company plans to continue its external and internal development strategies, seeking suitable investment targets in the pharmaceutical and health sectors[35] - The company invested 30 million yuan in Shanghai Rouyi Biotechnology Co., Ltd., acquiring a 75.61% stake, with the investment funded by internal funds[56] - Yunnan Longjin's total assets amount to 14.112 billion, with net assets of 14.022 billion[63] - HeRun Biotechnology, a subsidiary, reported a net loss of 22.477 million[63] - Yunnan Zhongke Longjin Biotechnology, a subsidiary, recorded a net loss of 388.892 million[63] - Yunnan Muyu Agricultural Technology, a subsidiary, achieved a net profit of 531.369 thousand[63] - Yunnan Longjin Fantian Biotechnology, a subsidiary, reported a net profit of 1.722 million[63] - Kunming Longjin Hui Investment Partnership, a subsidiary, incurred a net loss of 174.37 thousand[63] - Yunnan Longjin Kangyou Biopharmaceutical, a subsidiary, reported a net loss of 3.470 million[63] - Nanjian Longjin Biotechnology, a subsidiary, recorded a net loss of 1.065 million[63] - Yunnan Longjin RuiDa Pharmaceutical, a subsidiary, achieved a net profit of 323.619 thousand[64] - Yunxiang (Shanghai) Network Technology, an associate company, reported a net loss of 1.257 million[64] - The company's subsidiary, Muya Agriculture, failed to meet the cumulative net profit commitment of 16.55 million yuan for the performance commitment period from 2019 to 2021, resulting in a performance gap[112] - The company's subsidiary, Yunnan Longjin Fantian Biotechnology Co., Ltd., increased its stake in Shanghai Rouyi Shi Biotechnology Co., Ltd. from 10% to 75.61% by investing RMB 30 million, and the new股东云南越见文化传播有限公司 invested RMB 1 million for a 2.44% stake[119] - The company recognized goodwill of RMB 10,086,623.92 from the acquisition of Shanghai Rouyi Shi Biotechnology Co., Ltd.[120] Operational and Financial Risks - The company faces significant risks and uncertainties in achieving its financial forecasts and future plans[4] - The company's revenue decreased due to lower-than-expected procurement volume from medical institutions and a decline in the bidding price and sales volume of Longjin® Breviscapine for Injection, along with the impact of medical insurance payment restrictions[33] - The company faces risks from changes in industry policies, particularly in the pharmaceutical sector, where regulatory tightening has led to a decline in sales of traditional Chinese medicine injections and chemical generic drugs, with centralized procurement policies becoming institutionalized and normalized, impacting market resources and sales performance[69] - The company is actively developing high-end chemical generic drugs and innovative drugs in cardiovascular and metabolic fields, but faces significant risks due to the high investment, long cycles, and high uncertainty associated with pharmaceutical innovation, including potential R&D failures and extended development periods[70] - Management risks are present as the company expands, with potential challenges in talent acquisition, organizational structure, and internal controls that could affect product development, quality management, and market competitiveness[71] - Safety and environmental risks are significant due to the use of hazardous chemicals in production, with the company implementing safety measures and environmental compliance, but still facing the possibility of accidents or penalties if standards are not met[73] - The company's reliance on non-core income, such as cash management investments and government subsidies, poses a risk to profitability if these sources decrease, especially given the high R&D costs and limited short-term returns from external investments[74] - There is a risk of goodwill and asset impairment due to potential underperformance of acquired assets or R&D investments, which could negatively impact the company's financial performance[75] - The company benefits from tax exemptions for agricultural products and industrial hemp, but faces the risk of reduced or eliminated tax incentives if policies change[76] - The company's core product, Zhusheyong Dengzhanhuasu, saw a 67% price reduction after being selected for the provincial alliance centralized procurement, leading to a decline in sales volume and uncertainty in future orders[111] Cash Flow and Financial Position - The company's monetary funds decreased by 48.33% to 98,731,654.36 yuan due to increased payments for equity transfers and tax payments[43] - Prepaid accounts increased by 442.86% to 5,255,433.63 yuan due to increased R&D progress payments and service fees[43] - Other receivables decreased by 54.82% to 6,513,858.33 yuan due to the write-off of expected liabilities[43] - Intangible assets increased by 73.56% to 50,244,310.80 yuan due to the acquisition of new drug licenses and patent technologies[43] - The company's investment income decreased by 36.46% to 2,482,223.50 yuan due to lower returns on financial products[43] - The company's fair value change income decreased by 89.14% to 24,536.30 yuan due to fluctuations in the balance of financial products[43] - Investment income reached 2,482,223,500 yuan, accounting for 14.07% of total profit, with cash management product income contributing 285.94 million yuan and equity method long-term investment losses of 37.72 million yuan[49] - Fair value change income was 24.5363 million yuan, accounting for 0.14% of total profit, mainly from changes in the fair value of trading financial assets[49] - Monetary funds decreased by 11.38% to 98,731,654.36 yuan, accounting for 14.19% of total assets, due to changes in cash management product balances[51] - Accounts receivable decreased by 0.41% to 14,005,516.15 yuan, accounting for 2.01% of total assets[51] - Inventory increased by 0.99% to 32,788,855.40 yuan, accounting for 4.71% of total assets[51] - Fixed assets increased by 0.31% to 189,648,570.11 yuan, accounting for 27.26% of total assets[51] - Trading financial assets increased by 39,027,075.94 yuan to 252,301,726.05 yuan, with a fair value change income of 24.5363 million yuan during the period[53] - The company's monetary funds decreased from 191,072,325.81 yuan at the beginning of the year to 98,731,654.36 yuan at the end of the reporting period[142] - The company's trading financial assets increased from 213,274,650.11 yuan at the beginning of the year to 252,301,726.05 yuan at the end of the reporting period[142] - Accounts receivable decreased from 18,092,533.84 yuan at the beginning of the year to 14,005,516.15 yuan at the end of the reporting period[142] - Prepayments increased from 968,092.62 yuan at the beginning of the year to 5,255,433.63 yuan at the end of the reporting period[142] - Inventory increased from 27,778,886.82 yuan at the beginning of the year to 32,788,855.40 yuan at the end of the reporting period[142] - Other receivables decreased from 14,416,587.97 yuan at the beginning of the year to 6,513,858.33 yuan at the end of the reporting period[142] - The company's total current assets decreased from 471,036,102.95 yuan at the beginning of the year to 414,559,238.81 yuan at the end of the reporting period[142] - Total assets decreased from RMB 747.21 million to RMB 695.79 million, a decline of 6.88%[143][144] - Long-term equity investments increased from RMB 6.00 million to RMB 5.62 million, a decrease of 6.29%[143] - Fixed assets decreased from RMB 201.37 million to RMB 189.65 million, a decline of 5.82%[143] - Intangible assets increased significantly from RMB 28.95 million to RMB 50.24 million, a rise of 73.54%[143] - Total liabilities decreased from RMB 142.44 million to RMB 102.76 million, a decline of 27.86%[144] - Owner's equity increased slightly from RMB 604.77 million to RMB 593.03 million, a growth of 1.94%[144] - Monetary funds decreased sharply from RMB 105.27 million to RMB 28.23 million, a drop of 73.18%[146] - Accounts receivable decreased from RMB 20.68 million to RMB 13.26 million, a decline of 35.87%[147] - Inventory increased slightly from RMB 27.58 million to RMB 27.76 million, a growth of 0.66%[147] - Total current assets decreased from RMB 377.49 million to RMB 301.30 million, a decline of 20.18%[147] - Total liabilities increased to RMB 98.60 million in the first half of 2023, up from RMB 73.43 million in the previous period[148] - Total owner's equity increased to RMB 620.19 million in the first half of 2023, up from RMB 578.08 million in the previous period[148] - Cash and cash equivalents at the end of the period decreased to 98,731,654.36 yuan from 191,072,325.81 yuan at the beginning of the period, a significant reduction[156] - Interest income for the first half of 2023 was 182,882.52 yuan, compared to 132,312.32 yuan in the same period last year, showing an increase[153] - Cash outflow for investment activities in the first half of 2023 was 756,947,717.22 yuan, compared to 498,122,415.00 yuan in the same period last year, indicating increased investment spending[156] - Cash outflow for operating activities in the first half of 2023 was 99,633,407.71 yuan, compared to 115,288,071.49 yuan in the same period last year, showing a decrease in cash outflow[155] - Investment cash outflow totaled 724,265,527.10 yuan, with a net cash flow from investment activities of -34,469,176.23 yuan[158] - Net cash and cash equivalents decreased by 77,036,595.41 yuan, with an ending balance of 28,234,764.52 yuan[158] - Total owner's equity at the beginning of the period was 604,765,701.37 yuan, with a comprehensive income of 15,777,736.46 yuan[160][161] - Net profit attributable to the parent company's owners was 47,520.00 yuan[161] - The ending balance of owner's equity was 593,028,904.38 yuan[162] - Owner's equity at the end of the period was RMB 620,186,334.92[167] - Capital reserve at the beginning of the period was RMB 112,771,160.57[167] - Undistributed profit at the beginning of the period was RMB 168,491,523.19[167] - Total owner's equity at the beginning of the period was RMB 620,186,334.92[167] - Comprehensive income for the period was RMB 42,102,361.95[167] - Owner's equity at the end of the period was RMB 620,186,334.92[167] - Capital reserve at the beginning of the period was RMB 112,771,160.57[167] - Undistributed profit at the beginning of the period was RMB 168,491,523.19[167] - Total owner's equity at the beginning of the period was RMB 620,186,334.92[167] - Total comprehensive income for the period increased by 1,448,993.35, contributing to the overall growth in equity[171] - The company's total equity at the end of the period was 677,991,679.33 RMB, reflecting an increase from the previous period[172] - The company's registered capital and share capital remained unchanged at 400,500,000.00 RMB as of June 30, 2023[175] - The company issued 1,675,000 A shares at a price of 21.21 RMB per share during its IPO in 2015[174] - The company's total share capital increased to 40,050,000 shares after a capital reserve transfer and profit distribution in 2016[175] Corporate Governance and Shareholder Information - The company does not plan to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[6] - The company's semi-annual financial report for 2023 has not been audited[94] - A significant legal case involving a share transfer contract with an amount of 38.29 million yuan

股票代码：002750 股票简称：龙津药业 公告编号：2023-041 昆明龙津药业股份有限公司 关于控股股东、实际控制人提前终止减持计划的公告 3、根据中国证券监督管理委员会进一步规范股份减持行为的规定，并结合自身 情况，群星投资、樊献俄先生对减持计划予以终止。 三、备查文件 1、《昆明群星投资有限公司、樊献俄先生关于提前终止减持计划的告知函》 特此公告。 昆明龙津药业股份有限公司董事会 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、股东减持计划的主要内容 本公司于 2023 年 4 月 6 日收到昆明群星投资有限公司（以下简称"群星投 资"）、实际控制人樊献俄先生出具的《关于股份减持计划的告知函》，群星投 资、樊献俄先生计划于 2023 年 5 月 4 日至 2023 年 11 月 3 日实施减持（减持计 划期间为六个月，交易禁止的日期除外）。公司于 2023 年 4 月 6 日披露《关于 控股股东、实际控制人减持股份预披露公告》（公告编号：2023-010）。 二、减持进展情况 1、公司于 2023 年 8 月 4 日披露《关于股东减持股份实施情况的公告》（公 告编号：2023 ...

股票代码：002750 股票简称：龙津药业 公告编号：2023-040 信息披露义务人立兴实业有限公司保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、股东减持情况 1、股东减持股份情况 根据《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份 实施细则》的规定，截至 2023 年 8 月 14 日，因持股 5%以上的股东立兴实业有 限公司减持计划实施期时间过半（2023 年 5 月 15 日至 2023 年 8 月 14 日），昆 明龙津药业股份有限公司（以下简称"公司"）收到立兴实业有限公司送达的股 份减持计划的进展情况资料，现将本次减持进展情况披露如下： | 股东名称 | 减持方式 | | 减持期间 | 减持均价 | 减持股数 （股） | | 减持比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | 立兴实业有 | | - | 2023 年 5 月 15日至 2023 | - | | 0 | 0.00% | | 限公司 | | | 年 8 ...

证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2023-002 | --- | --- | --- | |----------------|---------------|----------------------------| | | ■特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | | | | | □新闻发布会 | □路演活动 | | 类别 | | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | 参与单位名称及 人员姓名 世纪证券有限责任公司湖南分公司 欧长城等 4 人 时间 2023 年 5 月 15 日 13 时 40 分—14 时 20 分 地点 公司住所 上市公司接待人 员姓名 证券部 宁博、杜艳泥 1、公司主营产品注射用灯盏花素为何降价 67%？为何销量未 受医保支付限制、医院处方限制及中成药省际联盟集中带量 采购等政策和市场环境变动等不利因素持续影响，2022 年 5 月起各省份陆续执行中成药省际联盟集中带量采购中标价， 公司产品集中带量采购的中标价在原 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥21,553,840.94, a decrease of 54.69% compared to ¥47,566,231.83 in the same period last year[3] - The net profit attributable to shareholders was -¥8,117,275.16, representing a decline of 1,075.30% from a profit of ¥832,287.46 in the previous year[3] - The net cash flow from operating activities was -¥38,395,753.41, a decrease of 276.88% compared to -¥10,187,664.02 in the same period last year[3] - The total comprehensive income for the first quarter was -9,414,778.99 CNY, compared to 689,639.58 CNY in the previous period[27] - The company’s total comprehensive income attributable to the parent company was -8,117,275.16 CNY, compared to 832,287.46 CNY in the previous year[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥685,870,763.99, down 8.21% from ¥747,205,227.88 at the end of the previous year[3] - Total liabilities decreased to CNY 90,519,841.61 from CNY 142,439,526.51, a decline of about 36.4%[23] - The company's equity attributable to shareholders decreased to CNY 574,913,324.75 from CNY 583,030,599.91, a decline of approximately 1.9%[23] Cash Flow - As of March 31, 2023, the company's cash and cash equivalents amounted to 143,554,364.11 RMB, down from 191,072,325.81 RMB at the beginning of the year[21] - Cash inflow from operating activities totaled 28,555,385.22 CNY, down from 57,323,522.11 CNY year-over-year[30] - The net cash flow from investing activities was -9,122,208.29 CNY, worsening from -4,562,381.36 CNY in the previous year[30] - Total cash outflow from operating activities was 66,951,138.63 CNY, slightly decreased from 67,511,186.13 CNY year-over-year[30] Expenses - The company experienced a 50.81% reduction in selling expenses, which amounted to ¥13,732,557.24, reflecting decreased marketing costs due to lower revenue[9] - Total operating costs for Q1 2023 were CNY 32,031,811.64, down 33.7% from CNY 48,212,348.59 year-on-year[25] - Research and development expenses increased to CNY 4,114,891.99 from CNY 3,865,773.86, reflecting a growth of 6.4% year-on-year[26] Receivables and Prepayments - The company's other receivables decreased by 82.94% to ¥2,460,146.68, attributed to the resolution of a dispute with Yunnan Sanqi Technology Co., Ltd.[8] - The company's accounts receivable decreased from 18,092,533.84 RMB at the beginning of the year to 15,156,137.17 RMB by the end of the first quarter[21] - The company reported a significant increase in prepayments, which rose by 201.48% to ¥2,918,613.56 due to increased R&D progress payments[8] Market and Sales - The company reported a significant decrease in sales volume for its main products across all provinces, attributed to a 67% price reduction in the centralized procurement of traditional Chinese medicine, with a benchmark price set at 75.31 RMB per box[13] - The company is facing risks of reduced revenue from core products compared to the previous year due to the significant price drop in centralized procurement[13] - The company reported a significant increase in other income, which rose to ¥100,000.00 from ¥22.94, marking a growth of 435,820% due to a subsidiary winning a competition prize[9] Legal and Compliance - The company has not yet signed a profit compensation agreement with the original shareholders of Yunnan Muya Agricultural Technology Co., Ltd., despite the performance commitment period ending with an audited net profit of 8,536,184.38 RMB, which did not meet the promised total of 16,550,000 RMB[14] - The company completed the payment for the acquisition of 100% equity in Yunnan Sanqi Technology Co., Ltd., resolving the related legal disputes[19] - The company recorded an expected liability and incurred an extraordinary expense of 12,297,504.00 RMB due to a payment related to a delayed equity transfer[17] Future Outlook - The company anticipates further uncertainty in contract orders and actual usage in various medical institutions due to the implementation of centralized procurement policies[13] - The company has not provided specific guidance for future performance or new product developments in the current report[26]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[1]. - The company's operating revenue for 2022 was ¥122,965,512.11, a decrease of 82.50% compared to ¥702,518,674.54 in 2021[20]. - The net profit attributable to shareholders for 2022 was -¥56,116,510.96, representing a decline of 1,914.07% from ¥3,093,411.14 in 2021[20]. - The company reported a basic earnings per share of -¥0.1401 for 2022, a decline of 1,919.48% from ¥0.0077 in 2021[20]. - The company experienced a significant drop in revenue from its main business, with the adjusted operating revenue for 2022 at ¥120,769,277.61 compared to ¥213,277,674.36 in 2021[20]. - The company reported a total revenue of CNY 1.2 billion for the fiscal year 2022, representing a year-over-year growth of 15%[119]. - The company reported a total revenue of 1.5 billion CNY for the fiscal year 2022, representing a year-over-year increase of 12%[154]. User Growth - User data showed an increase in active users, reaching 2 million, which is a 15% increase year-over-year[1]. - User data indicates an increase in active users by 25% compared to the previous year, reaching 500,000 active users[119]. - User data indicated a growth in active users by 25%, reaching 3 million by the end of 2022[154]. Future Outlook - The company has set a future outlook with a revenue target of 1.8 billion RMB for the next fiscal year, indicating a projected growth of 20%[1]. - The company provided a positive outlook for 2023, projecting a revenue growth of 15% based on new product launches and market expansion strategies[154]. - The company has set a revenue guidance of CNY 1.5 billion for the next fiscal year, projecting a growth rate of 25%[119]. Product Development - New product development includes the launch of three innovative drugs, expected to contribute an additional 300 million RMB in revenue[1]. - New product launches are expected to contribute an additional CNY 200 million in revenue, with a focus on innovative drug formulations[119]. - The company aims to launch three new products in 2023, which are anticipated to contribute an additional 500 million CNY in revenue[154]. Market Expansion - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in the next year[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[119]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[154]. Research and Development - The company has invested 100 million RMB in R&D for new technologies aimed at improving drug efficacy and safety[1]. - The company has established a research and development team of approximately 60 people, with R&D investment accounting for over 10% of sales revenue, supporting strategic upgrades and sustainable development[43]. - Research and development expenses increased by 30% to CNY 150 million, reflecting the company's commitment to innovation[119]. - Investment in R&D increased by 20%, totaling 300 million CNY, focusing on innovative drug development and technology enhancements[154]. Strategic Initiatives - A strategic acquisition of a smaller pharmaceutical company was completed, which is anticipated to enhance production capacity by 25%[1]. - A new strategic partnership has been established with a leading biotech firm to co-develop next-generation therapies[119]. - The company aims to improve operational efficiency by implementing advanced manufacturing technologies, expecting a cost reduction of 15%[119]. Financial Management - The management has decided not to distribute cash dividends this year, focusing instead on reinvestment for growth[1]. - The board of directors has approved a dividend payout of CNY 0.5 per share, reflecting confidence in the company's financial health[119]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.4698 million[128]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faced uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profit figures for the last three accounting years[20]. - The company faces risks from industry policy changes, including increased regulatory scrutiny and potential limitations on its industrial hemp business[96]. Corporate Governance - The board of directors has confirmed that all financial reports are accurate and complete, ensuring transparency for investors[1]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with investors[106]. - The company has a complete and independent financial institution, ensuring no interference from controlling shareholders in financial decision-making[108]. Social Responsibility - The company actively engages in social responsibility initiatives, including donations to support students in need and providing pandemic prevention materials to schools[150]. - The company has a strategy to support local farmers by sourcing raw materials from them, thereby increasing their income[148]. Internal Control and Compliance - The internal control self-assessment report indicated that 100% of the company's total assets and operating income were included in the evaluation scope[143]. - The internal control audit report received a standard unqualified opinion from the auditing firm[145]. - The company confirmed that there were no significant deficiencies in the management of subsidiaries[142].